Catalent收到两份483表格，涉及Sarepta基因疗法基地问题。
Catalent handed two Form 483s, including for Sarepta gene therapy site
生命科学资讯
生物技术与制药领域的最新动态
诺和诺德因收购的Catalent工厂收到FDA警告信。
Novo Nordisk hit with FDA warning letter over acquired Catalent factory
龙沙集团、Catalent与Recipharm领跑125亿美元吸入药物合同制造市场 - pharmiweb.com
Lonza Group, Catalent, and Recipharm Lead the $12.5 Billion Inhaled Drugs Contract Manufacturing Mar - pharmiweb.com
龙沙集团、Catalent与Recipharm引领2025-2033年125亿美元吸入药物合同制造市场：按服务、产品、终端用途及区域分析——ResearchAndMarkets.com - AI期刊
Lonza Group, Catalent, and Recipharm Lead the $12.5 Billion Inhaled Drugs Contract Manufacturing Market, 2025-2033: Insights by Service, Product, End-Use and Region - ResearchAndMarkets.com - The AI Journal